29.73
price up icon2.41%   0.70
after-market After Hours: 29.43 -0.30 -1.01%
loading
Apellis Pharmaceuticals Inc stock is traded at $29.73, with a volume of 1.31M. It is up +2.41% in the last 24 hours and down -11.68% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$29.03
Open:
$29.15
24h Volume:
1.31M
Relative Volume:
0.46
Market Cap:
$3.70B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-14.65
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-9.91%
1M Performance:
-11.68%
6M Performance:
-27.75%
1Y Performance:
-55.16%
1-Day Range:
Value
$29.15
$30.12
1-Week Range:
Value
$27.35
$30.38
52-Week Range:
Value
$24.34
$71.90

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Name
Apellis Pharmaceuticals Inc
Name
Phone
617-977-5700
Name
Address
100 FIFTH AVENUE, WALTHAM, KY
Name
Employee
702
Name
Twitter
@ApellisPharma
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
APLS's Discussions on Twitter

Compare APLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
29.73 3.70B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.96 107.38B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
693.23 76.18B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
659.81 39.45B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
249.16 32.14B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
112.76 27.03B 3.30B -501.07M 1.03B -2.1146

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-17-24 Downgrade Goldman Buy → Neutral
Nov-21-24 Initiated Morgan Stanley Equal-Weight
Oct-25-24 Initiated RBC Capital Mkts Sector Perform
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-16-24 Initiated William Blair Outperform
May-31-24 Initiated Piper Sandler Neutral
Feb-05-24 Upgrade Jefferies Hold → Buy
Dec-14-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-09-23 Initiated Goldman Buy
Nov-02-23 Initiated Mizuho Neutral
Oct-06-23 Upgrade JP Morgan Neutral → Overweight
Sep-15-23 Upgrade Wells Fargo Equal Weight → Overweight
Aug-29-23 Reiterated Citigroup Buy
Aug-03-23 Downgrade JP Morgan Overweight → Neutral
Aug-01-23 Downgrade BofA Securities Buy → Neutral
Jan-03-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-10-22 Downgrade Jefferies Buy → Hold
Jul-19-22 Initiated H.C. Wainwright Buy
Jun-17-22 Resumed Stifel Buy
Apr-14-22 Downgrade ROTH Capital Neutral → Sell
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Downgrade ROTH Capital Buy → Neutral
Sep-10-21 Reiterated BMO Capital Markets Outperform
Sep-10-21 Reiterated Credit Suisse Neutral
Sep-10-21 Reiterated Needham Buy
Sep-10-21 Reiterated Oppenheimer Outperform
Sep-10-21 Downgrade Wedbush Outperform → Neutral
Aug-19-21 Initiated Jefferies Buy
Aug-19-21 Upgrade Wedbush Neutral → Outperform
May-21-21 Initiated UBS Buy
Apr-16-21 Initiated Goldman Buy
Nov-19-20 Initiated Needham Buy
Sep-01-20 Initiated Stifel Buy
Jul-20-20 Initiated ROTH Capital Buy
Jun-17-20 Initiated BTIG Research Neutral
Apr-01-20 Initiated Raymond James Strong Buy
Mar-31-20 Initiated BMO Capital Markets Outperform
Mar-11-20 Upgrade Wedbush Underperform → Neutral
Jan-07-20 Initiated SVB Leerink Mkt Perform
Dec-19-19 Initiated BofA/Merrill Buy
Nov-22-19 Initiated Wedbush Underperform
Nov-05-19 Initiated Credit Suisse Neutral
Aug-01-19 Reiterated Cantor Fitzgerald Overweight
Jul-12-19 Upgrade JP Morgan Neutral → Overweight
Mar-29-19 Initiated Robert W. Baird Outperform
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Jul-30-18 Upgrade B. Riley FBR Neutral → Buy
May-24-18 Initiated Cantor Fitzgerald Overweight
Apr-12-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Feb-08-18 Initiated B. Riley FBR, Inc. Buy
View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

pulisher
Jan 16, 2025

IC-MPGN Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Novartis, Apellis Pharmaceuticals - The Globe and Mail

Jan 16, 2025
pulisher
Jan 16, 2025

IC-MPGN Market Revenue to Expand Significantly by 2034, States - openPR

Jan 16, 2025
pulisher
Jan 15, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect - AccessWire

Jan 15, 2025
pulisher
Jan 15, 2025

Layoff Tracker: Apellis, Barinthus, Repare Among Latest to Trim Workforces - BioSpace

Jan 15, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 By Investing.com - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals chief people officer sells $45,894 in stock By Investing.com - Investing.com Australia

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals VP sells shares worth $22,473 By Investing.com - Investing.com Canada

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals CFO sells shares worth $62,283 By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals chief development officer sells shares worth $7,577 By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $62,279.00 in Stock - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

David O. Watson Sells 4,965 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 By Investing.com - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock By Investing.com - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals officer sells shares worth $77,065 By Investing.com - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals officer sells shares worth $77,065 - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals CFO sells shares worth $62,283 - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals chief people officer sells $45,894 in stock - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

James George Chopas Sells 783 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $179,288.90 in Stock - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals general counsel sells shares worth $142,505 By Investing.com - Investing.com UK

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals chief business officer sells shares totaling $45,894 - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

Apellis Pharmaceuticals VP sells shares worth $22,473 - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

HC Wainwright Reaffirms "Buy" Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation - AccessWire

Jan 13, 2025
pulisher
Jan 13, 2025

Apellis stock jumps 8% on preliminary Q4 results, updates - MSN

Jan 13, 2025
pulisher
Jan 13, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpHere's What Happened - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Apellis Pharmaceuticals Reports Strong Growth and Leadership Changes - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Apellis reports $709 million in 2024 revenue, plans for growth - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Apellis reports $709 million in 2024 revenue, plans for growth By Investing.com - Investing.com UK

Jan 13, 2025
pulisher
Jan 13, 2025

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Apellis Reports Strong $709M Revenue as SYFOVRE Sales Surge 120%, Announces Leadership Changes - StockTitan

Jan 13, 2025
pulisher
Jan 13, 2025

APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm - AccessWire

Jan 13, 2025
pulisher
Jan 13, 2025

Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.

Jan 13, 2025
pulisher
Jan 10, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownHere's Why - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Apellis Announces Keli Walbert to Join the Board of Directors - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

What’s Driving Apellis Pharmaceuticals Stock Down? - TipRanks

Jan 10, 2025
pulisher
Jan 10, 2025

Apellis Pharmaceuticals Strengthens Board with TEPEZZA Launch Veteran Keli Walbert - StockTitan

Jan 10, 2025
pulisher
Jan 09, 2025

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire

Jan 09, 2025
pulisher
Jan 09, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation - AccessWire

Jan 09, 2025
pulisher
Jan 08, 2025

Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 2,816 Shares of Stock - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Apellis Pharmaceuticals chief medical officer sells $95,214 in stock - Investing.com

Jan 08, 2025
pulisher
Jan 08, 2025

Apellis Pharmaceuticals chief medical officer sells $95,214 in stock By Investing.com - Investing.com UK

Jan 08, 2025
pulisher
Jan 07, 2025

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 07, 2025
pulisher
Jan 07, 2025

Apellis Pharmaceuticals Awards Equity Inducement Grant to New Employee - StockTitan

Jan 07, 2025
pulisher
Jan 06, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out - AccessWire

Jan 06, 2025
pulisher
Jan 06, 2025

Apellis Pharmaceuticals To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart

Jan 06, 2025
pulisher
Jan 06, 2025

UNITY Biotech Appoints SYFOVRE Developer Dr. Grossi as CMO Ahead of Key DME Trial Results - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 06, 2025

Apellis Pharmaceuticals Inc Stock (APLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.22
price up icon 4.89%
$30.95
price up icon 0.68%
$72.47
price up icon 0.01%
$366.39
price up icon 1.31%
biotechnology ONC
$205.34
price up icon 1.79%
$112.76
price down icon 0.80%
Cap:     |  Volume (24h):